25 XP   0   0   10

Aptose Biosciences Inc
Buy, Hold or Sell?

Let's analyse Aptose together

PenkeI guess you are interested in Aptose Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aptose Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Aptose Biosciences Inc

I send you an email if I find something interesting about Aptose Biosciences Inc.

Quick analysis of Aptose (30 sec.)










What can you expect buying and holding a share of Aptose? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.50
Expected worth in 1 year
$-1.99
How sure are you?
36.8%

+ What do you gain per year?

Total Gains per Share
$-2.49
Return On Investment
-149.7%

For what price can you sell your share?

Current Price per Share
$1.66
Expected price per share
$1.36 - $2.18
How sure are you?
50%

1. Valuation of Aptose (5 min.)




Live pricePrice per Share (EOD)

$1.66

Intrinsic Value Per Share

$-28.40 - $-21.54

Total Value Per Share

$-27.90 - $-21.05

2. Growth of Aptose (5 min.)




Is Aptose growing?

Current yearPrevious yearGrowGrow %
How rich?$7.7m$60.4m-$39.1m-183.5%

How much money is Aptose making?

Current yearPrevious yearGrowGrow %
Making money-$12.2m-$13.9m$1.6m13.7%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Aptose (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#714 / 1031

Most Revenue
#886 / 1031

Most Profit
#622 / 1031

Most Efficient
#358 / 1031

What can you expect buying and holding a share of Aptose? (5 min.)

Welcome investor! Aptose's management wants to use your money to grow the business. In return you get a share of Aptose.

What can you expect buying and holding a share of Aptose?

First you should know what it really means to hold a share of Aptose. And how you can make/lose money.

Speculation

The Price per Share of Aptose is $1.66. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aptose.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aptose, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.50. Based on the TTM, the Book Value Change Per Share is $-0.62 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.67 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aptose.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.73-43.9%-0.78-47.2%-0.89-53.8%-0.75-44.9%-0.51-30.9%
Usd Book Value Change Per Share-0.38-23.1%-0.62-37.4%-0.67-40.1%-0.02-1.2%0.020.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.38-23.1%-0.62-37.4%-0.67-40.1%-0.02-1.2%0.020.9%
Usd Price Per Share2.80-2.17-1.01-3.05-2.90-
Price to Earnings Ratio-0.96--0.67--0.30--1.10--2.63-
Price-to-Total Gains Ratio-7.32--3.79--1.53-7.18-4.63-
Price to Book Ratio5.66-2.89-0.26-1.28-3.72-
Price-to-Total Gains Ratio-7.32--3.79--1.53-7.18-4.63-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.66
Number of shares602
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.62-0.02
Usd Total Gains Per Share-0.62-0.02
Gains per Quarter (602 shares)-374.06-11.78
Gains per Year (602 shares)-1,496.22-47.13
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1496-15060-47-57
20-2992-30020-94-104
30-4489-44980-141-151
40-5985-59940-189-198
50-7481-74900-236-245
60-8977-89860-283-292
70-10474-104820-330-339
80-11970-119780-377-386
90-13466-134740-424-433
100-14962-149700-471-480

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%2.036.00.05.3%6.098.00.05.8%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%5.015.00.025.0%14.024.00.036.8%36.068.00.034.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.038.00.0%0.00.0104.00.0%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%5.015.00.025.0%14.024.00.036.8%36.068.00.034.6%

Fundamentals of Aptose

About Aptose Biosciences Inc

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Fundamental data was last updated by Penke on 2024-03-20 10:05:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Aptose Biosciences Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Aptose earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aptose to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aptose Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--159.2%+159.2%
TTM--202.3%+202.3%
YOY--263.0%+263.0%
5Y--452.4%+452.4%
10Y--589.0%+589.0%
1.1.2. Return on Assets

Shows how efficient Aptose is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aptose to the Biotechnology industry mean.
  • -54.8% Return on Assets means that Aptose generated $-0.55 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aptose Biosciences Inc:

  • The MRQ is -54.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -40.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-54.8%TTM-40.4%-14.4%
TTM-40.4%YOY-19.5%-20.9%
TTM-40.4%5Y-22.0%-18.4%
5Y-22.0%10Y-24.5%+2.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-54.8%-12.5%-42.3%
TTM-40.4%-12.2%-28.2%
YOY-19.5%-11.2%-8.3%
5Y-22.0%-13.3%-8.7%
10Y-24.5%-14.6%-9.9%
1.1.3. Return on Equity

Shows how efficient Aptose is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aptose to the Biotechnology industry mean.
  • -147.2% Return on Equity means Aptose generated $-1.47 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aptose Biosciences Inc:

  • The MRQ is -147.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -69.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-147.2%TTM-69.3%-77.9%
TTM-69.3%YOY-22.4%-46.9%
TTM-69.3%5Y-29.8%-39.5%
5Y-29.8%10Y-31.1%+1.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-147.2%-16.0%-131.2%
TTM-69.3%-15.8%-53.5%
YOY-22.4%-13.9%-8.5%
5Y-29.8%-18.2%-11.6%
10Y-31.1%-19.1%-12.0%

1.2. Operating Efficiency of Aptose Biosciences Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Aptose is operating .

  • Measures how much profit Aptose makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aptose to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aptose Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM--208.5%+208.5%
YOY--280.2%+280.2%
5Y--459.9%+459.9%
10Y--596.9%+596.9%
1.2.2. Operating Ratio

Measures how efficient Aptose is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aptose Biosciences Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.817-2.817
TTM-3.181-3.181
YOY-3.609-3.609
5Y-5.554-5.554
10Y-7.396-7.396

1.3. Liquidity of Aptose Biosciences Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Aptose is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.59 means the company has $1.59 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aptose Biosciences Inc:

  • The MRQ is 1.589. The company is able to pay all its short-term debts. +1
  • The TTM is 2.696. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.589TTM2.696-1.107
TTM2.696YOY8.064-5.368
TTM2.6965Y10.881-8.185
5Y10.88110Y10.037+0.844
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5893.987-2.398
TTM2.6964.440-1.744
YOY8.0645.569+2.495
5Y10.8816.158+4.723
10Y10.0376.492+3.545
1.3.2. Quick Ratio

Measures if Aptose is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aptose to the Biotechnology industry mean.
  • A Quick Ratio of 1.59 means the company can pay off $1.59 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aptose Biosciences Inc:

  • The MRQ is 1.592. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.335. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.592TTM3.335-1.743
TTM3.335YOY11.433-8.098
TTM3.3355Y13.399-10.064
5Y13.39910Y12.016+1.384
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5923.653-2.061
TTM3.3354.158-0.823
YOY11.4335.515+5.918
5Y13.3996.012+7.387
10Y12.0166.206+5.810

1.4. Solvency of Aptose Biosciences Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Aptose assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aptose to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.63 means that Aptose assets are financed with 62.8% credit (debt) and the remaining percentage (100% - 62.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aptose Biosciences Inc:

  • The MRQ is 0.628. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.427. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.628TTM0.427+0.200
TTM0.427YOY0.131+0.296
TTM0.4275Y0.170+0.257
5Y0.17010Y0.155+0.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6280.336+0.292
TTM0.4270.330+0.097
YOY0.1310.267-0.136
5Y0.1700.367-0.197
10Y0.1550.378-0.223
1.4.2. Debt to Equity Ratio

Measures if Aptose is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aptose to the Biotechnology industry mean.
  • A Debt to Equity ratio of 168.5% means that company has $1.68 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aptose Biosciences Inc:

  • The MRQ is 1.685. The company is just able to pay all its debts with equity.
  • The TTM is 0.741. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.685TTM0.741+0.944
TTM0.741YOY0.153+0.589
TTM0.7415Y0.246+0.495
5Y0.24610Y0.214+0.031
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6850.376+1.309
TTM0.7410.398+0.343
YOY0.1530.334-0.181
5Y0.2460.431-0.185
10Y0.2140.476-0.262

2. Market Valuation of Aptose Biosciences Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aptose generates.

  • Above 15 is considered overpriced but always compare Aptose to the Biotechnology industry mean.
  • A PE ratio of -0.96 means the investor is paying $-0.96 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aptose Biosciences Inc:

  • The EOD is -0.569. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.960. Based on the earnings, the company is expensive. -2
  • The TTM is -0.665. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.569MRQ-0.960+0.391
MRQ-0.960TTM-0.665-0.295
TTM-0.665YOY-0.299-0.366
TTM-0.6655Y-1.097+0.431
5Y-1.09710Y-2.632+1.535
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.569-2.697+2.128
MRQ-0.960-2.422+1.462
TTM-0.665-2.709+2.044
YOY-0.299-4.116+3.817
5Y-1.097-6.257+5.160
10Y-2.632-6.478+3.846
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aptose Biosciences Inc:

  • The EOD is -0.619. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.044. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.719. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.619MRQ-1.044+0.425
MRQ-1.044TTM-0.719-0.325
TTM-0.719YOY-0.408-0.311
TTM-0.7195Y-1.507+0.788
5Y-1.50710Y-3.551+2.044
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.619-3.344+2.725
MRQ-1.044-2.939+1.895
TTM-0.719-3.486+2.767
YOY-0.408-5.592+5.184
5Y-1.507-8.464+6.957
10Y-3.551-8.872+5.321
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Aptose is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.66 means the investor is paying $5.66 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aptose Biosciences Inc:

  • The EOD is 3.353. Based on the equity, the company is fair priced.
  • The MRQ is 5.656. Based on the equity, the company is overpriced. -1
  • The TTM is 2.893. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.353MRQ5.656-2.303
MRQ5.656TTM2.893+2.763
TTM2.893YOY0.256+2.637
TTM2.8935Y1.277+1.616
5Y1.27710Y3.722-2.445
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.3532.198+1.155
MRQ5.6562.042+3.614
TTM2.8932.121+0.772
YOY0.2562.907-2.651
5Y1.2773.682-2.405
10Y3.7224.114-0.392
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aptose Biosciences Inc.

3.1. Institutions holding Aptose Biosciences Inc

Institutions are holding 9.806% of the shares of Aptose Biosciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30DRW Securities, LLC7.46410.033859282900
2023-09-30Sigma Planning Corp1.83550.01531457861457860
2023-09-30Nantahala Capital Management, LLC1.71840.0326136483-9749-6.6668
2023-09-30Carlson Capital LP1.3430.023310666600
2023-09-30Morgan Stanley - Brokerage Accounts0.5906046904-178-0.3781
2023-09-30Citadel Advisors Llc0.2185017353173530
2023-09-30Cetera Advisors LLC0.18880.000714996149960
2023-09-30TD Waterhouse Canada Inc0.09250.0003734500
2023-09-30The Toronto-Dominion Bank0.05790459945990
2023-09-30U.S. Bancorp0.02540202000
2023-09-30Wells Fargo & Co0.02160171200
2023-09-30Bank of America Corp0.01760140013001300
2023-12-31Gleason Group, Inc.0.01530.0007121600
2023-09-30Newbridge Financial Services Group, Inc.0.01050.0012832-133-13.7824
2023-09-30Royal Bank of Canada0.00910719-807-52.8834
2023-09-30Advisor Group Holdings, Inc.0.0053042000
2023-09-30Tower Research Capital LLC0.00240188159548.2759
2023-09-30Johnson Midwest Financial, LLC0.00190.00115100
2023-09-30Northwestern Mutual Wealth Management Co0.0017013300
2023-09-30Group One Trading, LP0.0014011500
Total 13.62150.10891081867+173326+16.0%

3.2. Funds holding Aptose Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Fidelity Nasdaq Composite Index0.01380216200
2023-07-31Dimensional Canadian Small Company0.00490.0002766-1-0.1304
2024-01-31DFA International Small Company I0.0047074100
2024-01-31DFA Global Small Company Institutional00200
Total 0.02340.00023671-10.0%

3.3. Insider Transactions

Insiders are holding 20.21% of the shares of Aptose Biosciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-09-22Bernd R SeizingerBUY170003.14

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Aptose Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.383-0.621+62%-0.666+74%-0.020-95%0.016-2564%
Book Value Per Share--0.4951.358-64%3.849-87%3.892-87%2.410-79%
Current Ratio--1.5892.696-41%8.064-80%10.881-85%10.037-84%
Debt To Asset Ratio--0.6280.427+47%0.131+379%0.170+269%0.155+305%
Debt To Equity Ratio--1.6850.741+127%0.153+1004%0.246+586%0.214+686%
Dividend Per Share----0%-0%-0%-0%
Eps---0.729-0.784+8%-0.894+23%-0.746+2%-0.513-30%
Free Cash Flow Per Share---0.671-0.700+4%-0.633-6%-0.549-18%-0.390-42%
Free Cash Flow To Equity Per Share---0.359-0.603+68%-0.631+76%0.007-5162%-0.009-97%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---21.545--------
Intrinsic Value_10Y_min---28.397--------
Intrinsic Value_1Y_max---1.648--------
Intrinsic Value_1Y_min---2.642--------
Intrinsic Value_3Y_max---5.342--------
Intrinsic Value_3Y_min---8.162--------
Intrinsic Value_5Y_max---9.504--------
Intrinsic Value_5Y_min---13.884--------
Market Cap26073288.000-69%43979040.00034005222.000+29%15891747.570+177%47981996.514-8%58165050.026-24%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio3.353-69%5.6562.893+96%0.256+2112%1.277+343%3.722+52%
Pe Ratio-0.569+41%-0.960-0.665-31%-0.299-69%-1.097+14%-2.632+174%
Price Per Share1.660-69%2.8002.165+29%1.012+177%3.055-8%2.901-3%
Price To Free Cash Flow Ratio-0.619+41%-1.044-0.719-31%-0.408-61%-1.507+44%-3.551+240%
Price To Total Gains Ratio-4.338+41%-7.318-3.787-48%-1.530-79%7.184-202%4.630-258%
Quick Ratio--1.5923.335-52%11.433-86%13.399-88%12.016-87%
Return On Assets---0.548-0.404-26%-0.195-64%-0.220-60%-0.245-55%
Return On Equity---1.472-0.693-53%-0.224-85%-0.298-80%-0.311-79%
Total Gains Per Share---0.383-0.621+62%-0.666+74%-0.020-95%0.016-2564%
Usd Book Value--7776000.00021324000.000-64%60456000.000-87%61126650.000-87%38616896.774-80%
Usd Book Value Change Per Share---0.383-0.621+62%-0.666+74%-0.020-95%0.016-2564%
Usd Book Value Per Share--0.4951.358-64%3.849-87%3.892-87%2.410-79%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.729-0.784+8%-0.894+23%-0.746+2%-0.513-30%
Usd Free Cash Flow---10535980.720-11001245.180+4%-9938298.763-6%-8616608.789-18%-6265034.269-41%
Usd Free Cash Flow Per Share---0.671-0.700+4%-0.633-6%-0.549-18%-0.390-42%
Usd Free Cash Flow To Equity Per Share---0.359-0.603+68%-0.631+76%0.007-5162%-0.009-97%
Usd Market Cap26073288.000-69%43979040.00034005222.000+29%15891747.570+177%47981996.514-8%58165050.026-24%
Usd Price Per Share1.660-69%2.8002.165+29%1.012+177%3.055-8%2.901-3%
Usd Profit---11447000.000-12266500.000+7%-13941500.000+22%-11682050.000+2%-7949393.504-31%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.383-0.621+62%-0.666+74%-0.020-95%0.016-2564%
 EOD+3 -5MRQTTM+17 -12YOY+14 -155Y+4 -2510Y+1 -28

4.2. Fundamental Score

Let's check the fundamental score of Aptose Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.569
Price to Book Ratio (EOD)Between0-13.353
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.592
Current Ratio (MRQ)Greater than11.589
Debt to Asset Ratio (MRQ)Less than10.628
Debt to Equity Ratio (MRQ)Less than11.685
Return on Equity (MRQ)Greater than0.15-1.472
Return on Assets (MRQ)Greater than0.05-0.548
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Aptose Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.911
Ma 20Greater thanMa 501.589
Ma 50Greater thanMa 1001.822
Ma 100Greater thanMa 2002.168
OpenGreater thanClose1.500
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets20,876
Total Liabilities13,100
Total Stockholder Equity7,776
 As reported
Total Liabilities 13,100
Total Stockholder Equity+ 7,776
Total Assets = 20,876

Assets

Total Assets20,876
Total Current Assets19,671
Long-term Assets1,205
Total Current Assets
Cash And Cash Equivalents 15,720
Short-term Investments 1,997
Other Current Assets 261
Total Current Assets  (as reported)19,671
Total Current Assets  (calculated)17,978
+/- 1,693
Long-term Assets
Property Plant Equipment 1,205
Long-term Assets  (as reported)1,205
Long-term Assets  (calculated)1,205
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities12,380
Long-term Liabilities720
Total Stockholder Equity7,776
Total Current Liabilities
Short-term Debt 390
Accounts payable 2,811
Other Current Liabilities 9,179
Total Current Liabilities  (as reported)12,380
Total Current Liabilities  (calculated)12,380
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt720
Long-term Liabilities  (as reported)720
Long-term Liabilities  (calculated)720
+/-0
Total Stockholder Equity
Common Stock443,938
Accumulated Other Comprehensive Income -4,315
Other Stockholders Equity -431,847
Total Stockholder Equity (as reported)7,776
Total Stockholder Equity (calculated)7,776
+/-0
Other
Capital Stock443,938
Cash and Short Term Investments 17,717
Common Stock Shares Outstanding 6,495
Liabilities and Stockholders Equity 20,876
Net Debt -14,610
Net Invested Capital 7,776
Net Working Capital 7,291
Property Plant and Equipment Gross 3,294
Short Long Term Debt Total 1,110



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-05-312014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-30
> Total Assets 
6,623
5,692
4,286
4,051
3,037
2,474
2,917
2,170
1,873
17,589
20,743
48,295
46,548
43,003
41,427
40,199
37,402
33,885
32,016
31,131
28,482
26,289
24,793
24,958
41,543
38,990
33,169
25,267
21,469
22,565
21,469
21,968
18,894
16,166
12,358
10,409
18,971
15,838
13,651
14,469
18,426
16,995
14,571
11,673
12,191
8,687
6,965
6,906
2,856
4,162
2,464
2,183
1,617
3,060
2,903
2,051
2,324
1,345
509
648
4,637
3,239
1,791
1,004
931
2,115
6,960
28,476
28,476
0
30,268
27,192
23,766
21,303
18,130
15,312
12,490
10,459
8,449
8,638
9,505
11,293
11,211
11,967
16,674
19,288
16,295
16,870
19,723
38,190
32,460
100,476
92,557
85,318
135,258
126,262
115,195
106,211
97,198
82,525
72,603
64,805
57,048
51,027
39,330
26,575
20,876
20,87626,57539,33051,02757,04864,80572,60382,52597,198106,211115,195126,262135,25885,31892,557100,47632,46038,19019,72316,87016,29519,28816,67411,96711,21111,2939,5058,6388,44910,45912,49015,31218,13021,30323,76627,19230,268028,47628,4766,9602,1159311,0041,7913,2394,6376485091,3452,3242,0512,9033,0601,6172,1832,4644,1622,8566,9066,9658,68712,19111,67314,57116,99518,42614,46913,65115,83818,97110,40912,35816,16618,89421,96821,46922,56521,46925,26733,16938,99041,54324,95824,79326,28928,48231,13132,01633,88537,40240,19941,42743,00346,54848,29520,74317,5891,8732,1702,9172,4743,0374,0514,2865,6926,623
   > Total Current Assets 
6,192
5,271
3,935
3,295
2,088
1,563
1,989
1,017
535
6,316
9,579
38,497
37,131
34,531
33,499
32,729
30,470
27,582
26,246
25,533
23,110
20,882
19,215
19,110
36,078
33,496
28,145
20,864
17,191
17,617
17,191
17,999
15,099
12,767
9,348
8,023
17,064
9,350
7,750
8,420
17,415
16,006
13,631
10,819
11,429
8,068
6,275
6,138
2,112
3,411
1,729
1,469
919
2,345
2,171
1,330
2,234
1,271
443
595
4,592
3,202
1,765
988
918
2,103
6,949
28,460
28,460
0
30,139
27,020
23,532
21,000
17,832
15,000
12,179
10,172
8,191
8,426
9,316
11,127
11,065
11,825
16,524
19,057
16,065
16,486
17,664
36,265
30,608
98,766
90,986
83,862
133,945
125,076
114,144
105,305
96,266
81,737
71,874
64,193
56,577
49,519
37,929
25,259
19,671
19,67125,25937,92949,51956,57764,19371,87481,73796,266105,305114,144125,076133,94583,86290,98698,76630,60836,26517,66416,48616,06519,05716,52411,82511,06511,1279,3168,4268,19110,17212,17915,00017,83221,00023,53227,02030,139028,46028,4606,9492,1039189881,7653,2024,5925954431,2712,2341,3302,1712,3459191,4691,7293,4112,1126,1386,2758,06811,42910,81913,63116,00617,4158,4207,7509,35017,0648,0239,34812,76715,09917,99917,19117,61717,19120,86428,14533,49636,07819,11019,21520,88223,11025,53326,24627,58230,47032,72933,49934,53137,13138,4979,5796,3165351,0171,9891,5632,0883,2953,9355,2716,192
       Cash And Cash Equivalents 
1,944
1,124
1,616
892
949
456
331
882
468
136
4,204
33,989
11,931
1,794
10,089
1,810
4,595
1,136
2,819
762
1,192
2,247
2,144
660
14,351
2,384
1,620
786
5,560
4,596
5,560
2,212
5,157
9,009
7,196
2,445
12,019
6,167
1,952
1,313
3,202
4,936
3,468
2,667
6,780
4,856
4,446
4,930
791
2,316
845
632
214
1,844
1,887
933
1,740
819
104
311
4,171
2,835
1,516
634
568
1,637
6,498
17,848
17,848
0
15,183
12,361
9,961
13,731
11,283
8,289
5,194
9,732
7,865
7,932
8,967
7,917
7,946
10,631
15,408
17,944
15,056
15,299
16,581
26,898
20,686
79,842
59,754
54,112
99,727
117,393
87,083
83,343
75,095
39,114
36,991
40,034
27,991
36,970
22,762
8,400
15,720
15,7208,40022,76236,97027,99140,03436,99139,11475,09583,34387,083117,39399,72754,11259,75479,84220,68626,89816,58115,29915,05617,94415,40810,6317,9467,9178,9677,9327,8659,7325,1948,28911,28313,7319,96112,36115,183017,84817,8486,4981,6375686341,5162,8354,1713111048191,7409331,8871,8442146328452,3167914,9304,4464,8566,7802,6673,4684,9363,2021,3131,9526,16712,0192,4457,1969,0095,1572,2125,5604,5965,5607861,6202,38414,3516602,1442,2471,1927622,8191,1364,5951,81010,0891,79411,93133,9894,2041364688823314569498921,6161,1241,944
       Short-term Investments 
3,960
3,865
2,108
2,060
696
716
1,061
0
0
5,772
4,824
3,777
24,672
32,288
22,668
29,941
24,917
25,790
22,772
23,989
21,290
18,033
16,513
17,646
21,073
30,418
25,562
18,832
10,220
11,900
10,220
14,888
8,801
3,164
1,821
5,110
4,409
2,495
5,274
6,793
12,957
9,842
8,940
6,823
3,855
2,565
1,282
450
448
466
232
234
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,155
10,155
0
14,431
13,923
12,812
6,578
6,112
5,942
6,383
0
0
0
0
2,979
3,010
798
770
520
550
440
449
8,477
9,528
17,758
30,229
28,610
32,997
5,000
24,999
19,999
20,006
40,014
32,520
22,375
27,402
9,989
12,958
14,906
1,997
1,99714,90612,9589,98927,40222,37532,52040,01420,00619,99924,9995,00032,99728,61030,22917,7589,5288,4774494405505207707983,0102,97900006,3835,9426,1126,57812,81213,92314,431010,15510,1550000000000000002342324664484501,2822,5653,8556,8238,9409,84212,9576,7935,2742,4954,4095,1101,8213,1648,80114,88810,22011,90010,22018,83225,56230,41821,07317,64616,51318,03321,29023,98922,77225,79024,91729,94122,66832,28824,6723,7774,8245,772001,0617166962,0602,1083,8653,960
       Net Receivables 
144
141
141
137
127
130
331
68
67
340
482
0
528
449
0
0
528
449
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000004495280044952804823406768331130127137141141144
       Other Current Assets 
144
141
70
206
316
260
265
68
0
68
69
731
528
0
742
978
-1
-1
-1
-1
627
603
1
1
1
0
-1
0
1,412
1,122
1,412
898
1
594
330
468
636
0
-1
1
568
599
612
603
795
-1
547
758
873
629
652
603
704
501
284
397
494
451
339
284
421
367
249
354
350
466
451
456
454
0
525
736
760
692
438
769
602
440
326
493
349
231
109
396
97
205
139
101
95
168
109
141
117
117
115
129
116
141
131
133
101
121
346
257
162
217
261
26121716225734612110113313114111612911511711714110916895101139205973961092313494933264406027694386927607365250454456451466350354249367421284339451494397284501704603652629873758547-17956036125995681-1063646833059418981,4121,1221,4120-10111603627-1-1-1-19787420528731696806826526031620670141144
   > Long-term Assets 
432
422
351
755
949
911
928
1,153
1,338
11,273
11,164
9,798
9,417
8,471
7,929
7,470
6,932
6,302
5,771
5,598
5,373
5,406
5,578
5,848
5,465
5,494
5,023
4,403
4,278
4,947
4,278
3,969
3,795
3,399
3,010
2,386
1,908
6,489
5,901
6,049
1,011
989
940
854
763
619
690
768
744
751
735
714
699
715
732
722
90
75
66
53
45
36
26
16
12
11
11
17
0
0
129
0
233
303
298
313
311
288
258
212
190
166
147
142
150
231
230
384
2,059
1,925
1,852
1,710
1,571
1,456
1,313
1,186
1,051
906
932
788
729
612
471
1,508
1,401
1,316
1,205
1,2051,3161,4011,5084716127297889329061,0511,1861,3131,4561,5711,7101,8521,9252,0593842302311501421471661902122582883113132983032330129001711111216263645536675907227327156997147357517447686906197638549409891,0116,0495,9016,4891,9082,3863,0103,3993,7953,9694,2784,9474,2784,4035,0235,4945,4655,8485,5785,4065,3735,5985,7716,3026,9327,4707,9298,4719,4179,79811,16411,2731,3381,153928911949755351422432
       Property Plant Equipment 
432
422
351
343
253
260
133
339
401
475
551
172
167
119
104
170
206
184
267
349
505
838
1,055
1,098
1,072
1,144
1,118
1,079
1,161
1,344
1,161
1,260
1,280
1,194
1,112
804
710
600
504
470
437
383
321
245
192
132
213
212
191
178
159
139
127
121
112
101
90
75
66
53
45
36
26
16
12
11
11
17
17
0
129
96
233
303
298
265
311
288
258
187
190
166
147
142
150
231
230
384
2,059
1,925
1,852
1,710
1,571
1,456
1,313
1,186
1,051
906
932
788
729
612
471
1,508
1,401
1,316
1,205
1,2051,3161,4011,5084716127297889329061,0511,1861,3131,4561,5711,7101,8521,9252,059384230231150142147166190187258288311265298303233961290171711111216263645536675901011121211271391591781912122131321922453213834374705046007108041,1121,1941,2801,2601,1611,3441,1611,0791,1181,1441,0721,0981,055838505349267184206170104119167172551475401339133260253343351422432
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,339
0
0
605
395
389
389
408
443
440
465
1
445
462
511
1
483
510
520
532
550
549
531
518
566
573
605
618
609
570
488
477
556
553
573
577
574
571
594
620
620
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000000062062059457157457757355355647748857060961860557356651853154955053252051048315114624451465440443408389389395605001,339000000000000000
       Intangible Assets 
0
0
0
481
696
716
663
678
669
2,784
2,757
2,346
2,139
1,815
1,578
1,340
1,094
847
605
396
389
387
408
441
438
467
454
445
462
3,078
462
2,256
2,054
1,753
921
595
237
531
518
566
574
606
616
605
568
487
469
555
554
574
582
580
569
590
624
626
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
77
0
0
0
48
0
0
0
25
0
0
0
1
0
0
0
142
0
0
0
94
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000009400014200010002500048000770000000000000006266245905695805825745545554694875686056166065745665185312375959211,7532,0542,2564623,0784624454544674384414083873893966058471,0941,3401,5781,8152,1392,3462,7572,784669678663716696481000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
9,254
8,345
0
7,296
6,719
6,116
0
0
4,869
0
0
0
0
0
3,892
0
3,117
3,610
3,100
0
2,513
0
1,900
1,582
1,200
5,888
5,404
0
0
606
0
605
568
487
469
555
554
0
582
580
0
590
624
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
77
0
0
0
48
0
0
0
25
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
925
0
0
0
0
0
0
0
0
0
0
0
000000000009250000000000000002500048000770000000000000000624590058058205545554694875686050606005,4045,8881,2001,5821,90002,51303,1003,6103,11703,892000004,869006,1166,7197,29608,3459,254000000000000
> Total Liabilities 
504
843
492
755
633
586
795
882
1,071
1,834
896
2,408
1,421
1,985
1,482
3,814
3,206
2,042
2,170
2,245
2,741
3,135
2,820
3,906
4,990
4,617
5,792
4,275
4,276
6,610
4,276
11,396
12,148
13,140
12,303
12,730
12,905
12,333
11,683
13,758
13,600
14,243
15,206
15,547
14,591
12,301
12,230
14,567
1,460
1,884
1,360
2,696
3,181
1,711
1,141
1,186
1,234
1,411
1,586
2,616
1,508
1,595
1,400
1,762
2,561
3,607
3,323
2,267
2,267
0
1,657
2,003
2,179
1,237
1,268
1,698
1,431
1,392
1,551
1,317
1,755
1,006
1,335
1,765
2,205
2,401
2,370
2,789
4,299
4,434
5,032
6,550
5,320
6,099
6,102
7,347
5,789
8,026
8,518
8,289
7,319
9,315
10,234
13,286
13,337
12,789
13,100
13,10012,78913,33713,28610,2349,3157,3198,2898,5188,0265,7897,3476,1026,0995,3206,5505,0324,4344,2992,7892,3702,4012,2051,7651,3351,0061,7551,3171,5511,3921,4311,6981,2681,2372,1792,0031,65702,2672,2673,3233,6072,5611,7621,4001,5951,5082,6161,5861,4111,2341,1861,1411,7113,1812,6961,3601,8841,46014,56712,23012,30114,59115,54715,20614,24313,60013,75811,68312,33312,90512,73012,30313,14012,14811,3964,2766,6104,2764,2755,7924,6174,9903,9062,8203,1352,7412,2452,1702,0423,2063,8141,4821,9851,4212,4088961,8341,071882795586633755492843504
   > Total Current Liabilities 
504
843
492
755
633
651
795
882
1,004
1,834
896
2,408
1,421
1,984
1,482
3,815
3,205
2,042
2,170
2,246
2,741
3,135
2,821
3,906
4,991
4,617
5,792
4,275
4,276
3,976
4,276
3,258
3,393
13,140
2,828
2,738
2,754
2,304
1,701
2,597
2,369
2,079
2,461
2,732
2,242
12,301
12,230
14,567
1,460
1,884
1,360
2,696
3,181
1,711
1,141
1,186
1,234
1,411
1,586
2,616
1,508
1,595
1,400
1,762
2,561
2,991
2,725
1,781
1,781
0
1,657
2,003
2,179
1,237
1,268
1,698
1,431
1,392
1,551
1,317
1,755
1,006
1,335
1,765
2,205
2,401
2,370
2,789
2,977
3,219
3,908
5,539
4,426
5,323
5,444
6,812
5,369
7,705
8,300
8,174
7,309
9,312
10,233
12,284
12,419
11,972
12,380
12,38011,97212,41912,28410,2339,3127,3098,1748,3007,7055,3696,8125,4445,3234,4265,5393,9083,2192,9772,7892,3702,4012,2051,7651,3351,0061,7551,3171,5511,3921,4311,6981,2681,2372,1792,0031,65701,7811,7812,7252,9912,5611,7621,4001,5951,5082,6161,5861,4111,2341,1861,1411,7113,1812,6961,3601,8841,46014,56712,23012,3012,2422,7322,4612,0792,3692,5971,7012,3042,7542,7382,82813,1403,3933,2584,2763,9764,2764,2755,7924,6174,9913,9062,8213,1352,7412,2462,1702,0423,2053,8151,4821,9841,4212,4088961,8341,004882795651633755492843504
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,057
0
0
0
0
0
0
0
0
0
0
0
10,879
10,961
13,255
0
0
0
948
1,415
0
0
0
0
0
302
873
0
0
0
0
796
813
797
0
484
0
488
353
218
230
0
0
0
0
0
0
0
0
0
0
0
0
0
0
485
493
513
521
525
528
537
539
530
508
482
459
519
398
270
301
306
387
390
39038730630127039851945948250853053953752852552151349348500000000000000230218353488048407978137960000873302000001,41594800013,25510,96110,879000000000009,057000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
484
0
0
353
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
485
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000048500000000000000003530048400000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
504
843
492
0
0
0
0
882
1,004
1,834
896
1,428
716
1,208
458
2,034
1,677
593
650
289
446
947
510
960
2,169
2,730
2,003
1,783
1,999
1,408
1,999
852
710
1,899
583
504
540
511
185
1,032
968
386
929
928
716
324
246
274
329
371
565
367
694
462
234
220
173
345
118
312
173
332
206
692
631
179
267
598
595
0
393
220
437
121
101
376
254
85
97
1,317
1,758
1,009
1,324
1,765
362
1,146
1,187
1,315
1,170
1,240
1,174
1,960
2,017
1,903
1,529
2,171
1,608
2,914
1,630
1,699
1,144
2,393
2,416
6,326
5,519
3,501
2,811
2,8113,5015,5196,3262,4162,3931,1441,6991,6302,9141,6082,1711,5291,9032,0171,9601,1741,2401,1701,3151,1871,1463621,7651,3241,0091,7581,317978525437610112143722039305955982671796316922063321733121183451732202344626943675653713292742463247169289293869681,0321855115405045831,8997108521,9991,4081,9991,7832,0032,7302,1699605109474462896505931,6772,0344581,2087161,4288961,8341,0048820000492843504
       Other Current Liabilities 
0
0
0
755
633
651
795
0
0
0
0
980
705
776
1,024
1,781
1,528
1,449
1,521
1,957
2,295
2,188
2,310
2,945
2,821
1,888
3,789
2,492
2,276
2,568
2,276
2,406
2,683
-1
2,245
2,234
2,214
1,793
1,516
1,564
1,401
1,692
1,532
1,804
1,525
1,098
1,024
1,038
1,131
1,514
795
1,382
1,072
1,249
907
966
1,061
1,066
1,167
1,430
1,335
1,262
1,194
1,070
1,135
2,000
1,661
1,182
1,177
0
775
1,430
1,523
886
1,166
1,322
1,176
1,307
1,454
1,317
1,755
1,006
1,335
1,765
1,843
1,255
1,183
1,474
1,322
1,486
2,221
3,058
1,884
2,892
3,378
4,102
3,231
4,283
6,188
6,016
5,646
6,521
7,547
5,657
6,594
8,084
9,179
9,1798,0846,5945,6577,5476,5215,6466,0166,1884,2833,2314,1023,3782,8921,8843,0582,2211,4861,3221,4741,1831,2551,8431,7651,3351,0061,7551,3171,4541,3071,1761,3221,1668861,5231,43077501,1771,1821,6612,0001,1351,0701,1941,2621,3351,4301,1671,0661,0619669071,2491,0721,3827951,5141,1311,0381,0241,0981,5251,8041,5321,6921,4011,5641,5161,7932,2142,2342,245-12,6832,4062,2762,5682,2762,4923,7891,8882,8212,9452,3102,1882,2951,9571,5211,4491,5281,7811,0247767059800000795651633755000
   > Long-term Liabilities 
504
843
492
0
0
-65
0
882
67
1,834
896
1,428
716
1
458
-1
1
593
650
-1
446
947
-1
960
-1
2,730
2,003
1,783
1,999
2,634
1,999
8,138
8,755
10,956
9,474
9,992
10,151
10,029
9,983
11,162
11,231
12,165
12,745
12,815
12,350
11,203
11,206
13,529
329
371
565
1,315
2,109
462
234
220
173
345
419
1,186
173
332
206
692
1,427
615
598
487
0
0
882
0
655
350
101
376
254
85
97
0
0
0
0
0
362
1,146
1,187
1,315
1,322
1,215
1,124
1,011
894
776
658
535
420
321
218
115
10
3
1
1,002
918
817
720
7208179181,00213101152183214205356587768941,0111,1241,2151,3221,3151,1871,1463620000097852543761013506550882004875986151,4276922063321731,1864193451732202344622,1091,31556537132913,52911,20611,20312,35012,81512,74512,16511,23111,1629,98310,02910,1519,9929,47410,9568,7558,1381,9992,6341,9991,7832,0032,730-1960-1947446-16505931-145817161,4288961,834678820-6500492843504
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,322
1,215
1,124
1,011
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000001,0111,1241,2151,3220000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
6,120
4,849
3,794
3,295
2,404
1,888
2,121
1,289
803
15,755
19,848
45,887
45,127
41,018
39,945
36,385
34,196
31,842
29,846
28,886
25,741
23,154
21,974
21,053
36,554
34,373
27,377
20,992
17,193
15,955
17,193
10,571
6,746
3,026
55
-2,321
6,067
3,505
1,968
711
4,826
2,751
-635
-3,874
-2,400
-3,613
-5,266
-7,661
1,396
2,278
1,104
-514
-1,564
1,350
1,762
865
1,090
-66
-1,077
-1,968
3,129
1,644
392
-758
-1,631
-1,492
3,637
26,209
26,091
0
28,612
25,189
21,587
20,067
16,863
13,615
11,060
9,067
6,898
7,321
7,751
10,287
9,876
10,202
14,469
16,887
13,925
14,081
15,424
33,756
27,428
93,926
87,237
79,219
129,156
118,915
109,406
98,185
88,680
74,236
65,284
55,490
46,814
37,741
-478,006
13,786
7,776
7,77613,786-478,00637,74146,81455,49065,28474,23688,68098,185109,406118,915129,15679,21987,23793,92627,42833,75615,42414,08113,92516,88714,46910,2029,87610,2877,7517,3216,8989,06711,06013,61516,86320,06721,58725,18928,612026,09126,2093,637-1,492-1,631-7583921,6443,129-1,968-1,077-661,0908651,7621,350-1,564-5141,1042,2781,396-7,661-5,266-3,613-2,400-3,874-6352,7514,8267111,9683,5056,067-2,321553,0266,74610,57117,19315,95517,19320,99227,37734,37336,55421,05321,97423,15425,74128,88629,84631,84234,19636,38539,94541,01845,12745,88719,84815,7558031,2892,1211,8882,4043,2953,7944,8496,120
   Common Stock
0
0
0
0
0
0
0
0
0
0
47,934
76,636
78,063
74,961
75,445
76,155
75,466
75,358
74,442
77,735
76,505
76,649
80,499
87,754
104,432
111,370
108,394
106,182
110,231
122,152
122,141
114,900
121,428
123,972
127,342
131,663
142,196
137,705
134,687
211,923
149,634
158,239
161,009
217,649
151,593
130,186
127,692
148,844
148,144
154,941
155,914
155,357
154,583
163,946
172,584
172,787
173,688
164,634
170,988
165,007
175,743
175,690
170,473
169,327
165,549
166,644
165,717
196,242
195,356
0
197,722
190,396
175,469
179,560
166,285
161,005
172,125
174,393
172,345
171,844
176,869
186,216
197,258
231,923
240,778
253,081
254,715
261,072
267,250
291,238
291,344
365,490
366,252
366,337
429,457
429,523
429,651
429,795
429,795
437,386
437,412
437,441
437,469
437,520
437,946
439,100
443,938
443,938439,100437,946437,520437,469437,441437,412437,386429,795429,795429,651429,523429,457366,337366,252365,490291,344291,238267,250261,072254,715253,081240,778231,923197,258186,216176,869171,844172,345174,393172,125161,005166,285179,560175,469190,396197,7220195,356196,242165,717166,644165,549169,327170,473175,690175,743165,007170,988164,634173,688172,787172,584163,946154,583155,357155,914154,941148,144148,844127,692130,186151,593217,649161,009158,239149,634211,923134,687137,705142,196131,663127,342123,972121,428114,900122,141122,152110,231106,182108,394111,370104,43287,75480,49976,64976,50577,73574,44275,35875,46676,15575,44574,96178,06376,63647,9340000000000
   Retained Earnings -503,582-492,135-478,006-464,330-454,330-444,553-433,988-422,507-398,183-386,850-373,380-357,153-342,440-329,191-313,441-301,915-294,206-287,362-281,144-275,638-269,377-263,870-253,584-246,788-211,556-199,246-191,883-187,141-188,332-188,280-183,339-167,839-170,188-181,435-174,990-187,835-192,3520-193,130-194,006-185,404-192,015-190,723-194,007-194,035-198,592-197,026-188,644-194,503-186,285-195,005-193,600-192,312-182,929-174,694-174,464-173,399-171,048-164,027-173,772-147,703-149,003-172,044-181,586-180,493-172,964-161,153-162,871-147,380-149,311-151,368-149,450-142,007-134,840-128,297-116,860-99,664-115,188-99,664-89,404-85,311-81,412-72,003-66,669-58,438-52,983-50,658-48,994-44,393-43,308-41,582-39,923-35,956-34,203-33,068-30,813-28,255-26,689-25,560-25,500-24,064-23,047-21,767-22,587-22,695-21,644-21,022
   Accumulated Other Comprehensive Income 
432
351
351
343
316
326
1,193
339
335
6,519
207
143
167
191
113
113
237
-220
-147
-104
-72
-96
-66
-31
4,124
4,413
4,294
4,206
6,642
9,173
6,642
12,583
13,539
14,123
8,580
8,474
8,521
8,364
8,244
8,146
8,328
8,415
8,760
8,826
8,739
6,717
0
-3,286
0
0
0
-2,616
0
0
0
-2,882
-2,887
-2,747
-2,865
-2,774
0
0
0
-2,811
0
0
0
-2,689
-2,689
0
0
0
0
0
0
-58
0
0
0
-4,000
-92
-375
-821
-4,298
-4,318
-4,298
-4,313
-4,316
-4,307
-4,298
-4,303
-4,298
-4,298
-4,313
-4,315
-4,316
-4,316
-4,316
-4,316
-4,316
-4,316
-4,353
-4,333
-4,318
-4,314
-4,315
-4,315
-4,315-4,315-4,314-4,318-4,333-4,353-4,316-4,316-4,316-4,316-4,316-4,316-4,315-4,313-4,298-4,298-4,303-4,298-4,307-4,316-4,313-4,298-4,318-4,298-821-375-92-4,000000-58000000-2,689-2,689000-2,811000-2,774-2,865-2,747-2,887-2,882000-2,616000-3,28606,7178,7398,8268,7608,4158,3288,1468,2448,3648,5218,4748,58014,12313,53912,5836,6429,1736,6424,2064,2944,4134,124-31-66-96-72-104-147-2202371131131911671432076,5193353391,193326316343351351432
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,963
33,625
34,178
34,593
34,649
38,724
46,386
46,454
50,861
57,451
59,556
61,384
63,673
66,176
0
68,008
68,869
70,367
0
0
0070,36768,86968,008066,17663,67361,38459,55657,45150,86146,45446,38638,72434,64934,59334,17833,62532,963000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
26,710
26,142
26,138
25,539
23,855
24,609
24,992
26,450
26,028
35,924
47,896
76,557
78,028
75,030
75,788
76,195
75,541
75,371
74,386
77,984
76,471
76,233
80,478
-1
1
0
0
106,189
110,215
121,970
110,215
114,848
121,504
123,744
133,482
138,655
148,914
144,452
141,104
155,436
157,650
167,301
171,098
168,886
160,906
138,673
14,745
17,266
17,279
18,384
18,589
18,593
18,547
20,333
21,490
21,678
22,407
21,585
22,438
21,670
24,412
24,545
23,953
23,922
23,543
23,878
23,324
23,973
4,223
0
23,242
3,995
21,107
21,941
20,766
20,449
22,274
22,954
22,886
22,617
22,857
23,693
24,996
29,365
31,593
31,974
32,900
32,963
33,625
34,178
34,593
34,649
38,724
46,386
46,454
50,861
57,451
59,556
61,384
63,673
66,176
66,955
68,008
68,869
-433,632
-420,999
-431,847
-431,847-420,999-433,63268,86968,00866,95566,17663,67361,38459,55657,45150,86146,45446,38638,72434,64934,59334,17833,62532,96332,90031,97431,59329,36524,99623,69322,85722,61722,88622,95422,27420,44920,76621,94121,1073,99523,24204,22323,97323,32423,87823,54323,92223,95324,54524,41221,67022,43821,58522,40721,67821,49020,33318,54718,59318,58918,38417,27917,26614,745138,673160,906168,886171,098167,301157,650155,436141,104144,452148,914138,655133,482123,744121,504114,848110,215121,970110,215106,189001-180,47876,23376,47177,98474,38675,37175,54176,19575,78875,03078,02876,55747,89635,92426,02826,45024,99224,60923,85525,53926,13826,14226,710



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-50,632
Operating Income-50,632-50,632
 
Operating Expense (+$)
Research Development34,425
Selling General Administrative16,148
Selling And Marketing Expenses-
Operating Expense50,63250,573
 
Net Interest Income (+$)
Interest Income1,381
Interest Expense--
Other Finance Cost-0
Net Interest Income1,381
 
Pretax Income (+$)
Operating Income-50,632
Net Interest Income1,381
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-49,252-50,631
EBIT - interestExpense = 0
-49,252
-49,252
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--49,252
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-49,252
Tax Provision--
Net Income From Continuing Ops-49,252-49,252
Net Income-49,252
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-1-1,381
 

Technical Analysis of Aptose
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aptose. The general trend of Aptose is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aptose's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aptose Biosciences Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 1.6924 < 2.14 < 2.18.

The bearish price targets are: 1.36.

Tweet this
Aptose Biosciences Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aptose Biosciences Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aptose Biosciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aptose Biosciences Inc. The current macd is -0.08340781.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aptose price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Aptose. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Aptose price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Aptose Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartAptose Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aptose Biosciences Inc. The current adx is 32.04.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Aptose shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Aptose Biosciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aptose Biosciences Inc. The current sar is 1.41065802.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Aptose Biosciences Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aptose Biosciences Inc. The current rsi is 49.91. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Aptose Biosciences Inc Daily Relative Strength Index (RSI) ChartAptose Biosciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aptose Biosciences Inc. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aptose price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Aptose Biosciences Inc Daily Stochastic Oscillator ChartAptose Biosciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aptose Biosciences Inc. The current cci is 23.40.

Aptose Biosciences Inc Daily Commodity Channel Index (CCI) ChartAptose Biosciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aptose Biosciences Inc. The current cmo is 12.13.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Aptose Biosciences Inc Daily Chande Momentum Oscillator (CMO) ChartAptose Biosciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aptose Biosciences Inc. The current willr is -11.76470588.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Aptose Biosciences Inc Daily Williams %R ChartAptose Biosciences Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Aptose Biosciences Inc.

Aptose Biosciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aptose Biosciences Inc. The current atr is 0.13743461.

Aptose Biosciences Inc Daily Average True Range (ATR) ChartAptose Biosciences Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aptose Biosciences Inc. The current obv is -1,647,588.

Aptose Biosciences Inc Daily On-Balance Volume (OBV) ChartAptose Biosciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aptose Biosciences Inc. The current mfi is 46.35.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Aptose Biosciences Inc Daily Money Flow Index (MFI) ChartAptose Biosciences Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aptose Biosciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-16STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-27BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-31MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-22MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Aptose Biosciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aptose Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.911
Ma 20Greater thanMa 501.589
Ma 50Greater thanMa 1001.822
Ma 100Greater thanMa 2002.168
OpenGreater thanClose1.500
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Aptose with someone you think should read this too:
  • Are you bullish or bearish on Aptose? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aptose? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aptose Biosciences Inc

I send you an email if I find something interesting about Aptose Biosciences Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Aptose Biosciences Inc.

Receive notifications about Aptose Biosciences Inc in your mailbox!